{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:06:43Z","timestamp":1772816803197,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,9,18]],"date-time":"2012-09-18T00:00:00Z","timestamp":1347926400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1038\/bjc.2012.406","type":"journal-article","created":{"date-parts":[[2012,9,18]],"date-time":"2012-09-18T20:16:31Z","timestamp":1347999391000},"page":"1277-1285","source":"Crossref","is-referenced-by-count":28,"title":["Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours"],"prefix":"10.1038","volume":"107","author":[{"given":"M F","family":"Kozloff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L P","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Krzakowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T A","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T A","family":"Rado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Arriola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"De Castro Carpe\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R S","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Tarazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Rosbrook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Tortorici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A J","family":"Olszanski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R B","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,18]]},"reference":[{"key":"BFbjc2012406_CR1","first-page":"1253","volume":"9","author":"EM Berns","year":"2003","unstructured":"Berns EM, Klijn JG, Look MP, Grebenchtchikov N, Vossen R, Peters H, Geurts-Moespot A, Portengen H, van Staveren IL, Meijer-van Gelder ME, Bakker B, Sweep FC, Foekens JA (2003) Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. Clin Cancer Res 9: 1253\u20131258","journal-title":"Clin Cancer Res"},{"key":"BFbjc2012406_CR2","first-page":"1255","volume":"143","author":"LF Brown","year":"1993","unstructured":"Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR (1993) Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 143: 1255\u20131262","journal-title":"Am J Pathol"},{"issue":"Suppl 1","key":"BFbjc2012406_CR3","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1038\/onc.2009.196","volume":"28","author":"HA Burris","year":"2009","unstructured":"Burris HA (2009) Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene 28 (Suppl 1): S4\u2013S13","journal-title":"Oncogene"},{"key":"BFbjc2012406_CR4","doi-asserted-by":"publisher","first-page":"4708","DOI":"10.1200\/JCO.2007.15.9566","volume":"26","author":"EE Cohen","year":"2008","unstructured":"Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26: 4708\u20134713","journal-title":"J Clin Oncol"},{"key":"BFbjc2012406_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2165\/00003088-199733030-00002","volume":"33","author":"SB Duffull","year":"1997","unstructured":"Duffull SB, Robinson BA (1997) Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 33: 161\u2013183","journal-title":"Clin Pharmacokinet"},{"key":"BFbjc2012406_CR6","doi-asserted-by":"publisher","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","volume":"14","author":"DD Hu-Lowe","year":"2008","unstructured":"Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O\u2019Connor P, Shalinsky DR, Bender SL (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14: 7272\u20137283","journal-title":"Clin Cancer Res"},{"key":"BFbjc2012406_CR7","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335\u20132342","journal-title":"N Engl J Med"},{"key":"BFbjc2012406_CR8","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/sj.bjc.6690248","volume":"79","author":"N Ikeda","year":"1999","unstructured":"Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, Sho M, Nakajima Y, Kanehiro H, Hisanaga M, Nakano H, Miyake M (1999) Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 79: 1553\u20131563","journal-title":"Br J Cancer"},{"key":"BFbjc2012406_CR9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s11906-007-0058-7","volume":"9","author":"M Jain","year":"2007","unstructured":"Jain M, Townsend RR (2007) Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep 9: 320\u2013328","journal-title":"Curr Hypertens Rep"},{"key":"BFbjc2012406_CR10","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1111\/j.1349-7006.2007.00620.x","volume":"98","author":"VL Keedy","year":"2007","unstructured":"Keedy VL, Sandler AB (2007) Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Sci 98: 1825\u20131830","journal-title":"Cancer Sci"},{"key":"BFbjc2012406_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s10120-006-0411-6","volume":"10","author":"M Kobayashi","year":"2007","unstructured":"Kobayashi M, Oba K, Sakamoto J, Kondo K, Nagata N, Okabayashi T, Namikawa T, Hanazaki K (2007) Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan. Gastric Cancer 10: 52\u201357","journal-title":"Gastric Cancer"},{"issue":"8","key":"BFbjc2012406_CR12","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1038\/bjc.2012.407","volume":"107","author":"L P Martin","year":"2012","unstructured":"Martin LP, Kozloff MF, Herbst RS, Samuel TA, Kim S, Rosbrook B, Tortorici M, Chen Y, Tarazi J, Olszanski AJ, Rado T, Starr A, Cohen RB (2012) Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. Br J Cancer doi:10.1038\/bjc.2012.407; e-pub ahead of print","journal-title":"British Journal of Cancer"},{"key":"BFbjc2012406_CR13","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666\u20132676","journal-title":"N Engl J Med"},{"key":"BFbjc2012406_CR14","unstructured":"Monsarrat B, Alvinerie P, Wright M, Dubois J, Gueritte-Voegelein F, Guenard D, Donehower RC, Rowinsky EK (1993) Hepatic metabolism and biliary excretion of Taxol in rats and humans. J Natl Cancer Inst Monogr 39\u201346"},{"key":"BFbjc2012406_CR15","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/annonc\/mdi310","volume":"16","author":"M Moore","year":"2005","unstructured":"Moore M, Hirte HW, Siu L, Oza A, Hotte SJ, Petrenciuc O, Cihon F, Lathia C, Schwartz B (2005) Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on\/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16: 1688\u20131694","journal-title":"Ann Oncol"},{"key":"BFbjc2012406_CR16","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1007\/s10637-009-9321-x","volume":"28","author":"I Okamoto","year":"2010","unstructured":"Okamoto I, Miyazaki M, Morinaga R, Kaneda H, Ueda S, Hasegawa Y, Satoh T, Kawada A, Fukuoka M, Fukino K, Tanigawa T, Nakagawa K (2010) Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Invest New Drugs 28: 844\u2013853","journal-title":"Invest New Drugs"},{"key":"BFbjc2012406_CR17","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1093\/annonc\/mdq020","volume":"21","author":"M Reck","year":"2010","unstructured":"Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C (2010) Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21: 1804\u20131809","journal-title":"Ann Oncol"},{"key":"BFbjc2012406_CR18","doi-asserted-by":"publisher","first-page":"7947","DOI":"10.1158\/1078-0432.CCR-08-0864","volume":"14","author":"AD Ricart","year":"2008","unstructured":"Ricart AD, Berlin JD, Papadopoulos KP, Syed S, Drolet DW, Quaratino-Baker C, Horan J, Chick J, Vermeulen W, Tolcher AW, Rowinsky EK, Rothenberg ML (2008) Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors. Clin Cancer Res 14: 7947\u20137955","journal-title":"Clin Cancer Res"},{"key":"BFbjc2012406_CR19","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1200\/JCO.2008.21.7034","volume":"27","author":"BI Rini","year":"2009","unstructured":"Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP (2009) Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27: 4462\u20134468","journal-title":"J Clin Oncol"},{"key":"BFbjc2012406_CR20","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S1470-2045(07)70285-1","volume":"8","author":"O Rixe","year":"2007","unstructured":"Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8: 975\u2013984","journal-title":"Lancet Oncol"},{"key":"BFbjc2012406_CR21","doi-asserted-by":"publisher","first-page":"5474","DOI":"10.1200\/JCO.2005.04.192","volume":"23","author":"HS Rugo","year":"2005","unstructured":"Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23: 5474\u20135483","journal-title":"J Clin Oncol"},{"key":"BFbjc2012406_CR22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/modpathol.3800034","volume":"17","author":"RS Saad","year":"2004","unstructured":"Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF (2004) Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 17: 197\u2013203","journal-title":"Mod Pathol"},{"key":"BFbjc2012406_CR23","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013\u20132019","journal-title":"J Clin Oncol"},{"key":"BFbjc2012406_CR24","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542\u20132550","journal-title":"N Engl J Med"},{"key":"BFbjc2012406_CR25","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1200\/JCO.2009.26.1321","volume":"28","author":"G Scagliotti","year":"2010","unstructured":"Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrao Miziara JE, Balint B, De Marinis F, Keller A, Aren O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N (2010) Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28: 1835\u20131842","journal-title":"J Clin Oncol"},{"key":"BFbjc2012406_CR26","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1200\/JCO.2008.20.8355","volume":"27","author":"JH Schiller","year":"2009","unstructured":"Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J (2009) Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 27: 3836\u20133841","journal-title":"J Clin Oncol"},{"key":"BFbjc2012406_CR27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/annonc\/mdp489","volume":"21","author":"S Sharma","year":"2010","unstructured":"Sharma S, Abhyankar V, Burgess RE, Infante J, Trowbridge RC, Tarazi J, Kim S, Tortorici M, Chen Y, Robles RL (2010) A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann Oncol 21: 297\u2013304","journal-title":"Ann Oncol"},{"key":"BFbjc2012406_CR28","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/S0140-6736(08)60661-3","volume":"371","author":"JP Spano","year":"2008","unstructured":"Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, Letourneau R, Bajetta E, Pithavala Y, Bycott P, Trask P, Liau K, Ricart AD, Kim S, Rixe O (2008) Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 371: 2101\u20132108","journal-title":"Lancet"},{"key":"BFbjc2012406_CR29","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2217\/14622416.8.7.803","volume":"8","author":"H Steed","year":"2007","unstructured":"Steed H, Sawyer MB (2007) Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel. Pharmacogenomics 8: 803\u2013815","journal-title":"Pharmacogenomics"},{"key":"BFbjc2012406_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1513\/pats.200809-110LC","volume":"6","author":"TE Stinchcombe","year":"2009","unstructured":"Stinchcombe TE, Socinski MA (2009) Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 6: 233\u2013241","journal-title":"Proc Am Thorac Soc"},{"key":"BFbjc2012406_CR31","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","volume":"23","author":"D Strumberg","year":"2005","unstructured":"Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S (2005) Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23: 965\u2013972","journal-title":"J Clin Oncol"},{"key":"BFbjc2012406_CR32","first-page":"46","volume":"46","author":"The Medical Letter Online","year":"2004","unstructured":"The Medical Letter Online (2004) Two new drugs for colon cancer. Med Lett Drugs Ther 46: 46\u201348","journal-title":"Med Lett Drugs Ther"},{"key":"BFbjc2012406_CR33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"BFbjc2012406_CR34","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176\u2013181","journal-title":"Semin Radiat Oncol"},{"key":"BFbjc2012406_CR35","doi-asserted-by":"publisher","first-page":"6086","DOI":"10.1158\/1078-0432.CCR-04-0779","volume":"10","author":"MA Villalona-Calero","year":"2004","unstructured":"Villalona-Calero MA, Ritch P, Figueroa JA, Otterson GA, Belt R, Dow E, George S, Leonardo J, McCachren S, Miller GL, Modiano M, Valdivieso M, Geary R, Oliver JW, Holmlund J (2004) A phase I\/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res 10: 6086\u20136093","journal-title":"Clin Cancer Res"},{"key":"BFbjc2012406_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","volume":"9","author":"S Wu","year":"2008","unstructured":"Wu S, Chen JJ, Kudelka A, Lu J, Zhu X (2008) Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 9: 117\u2013123","journal-title":"Lancet Oncol"},{"key":"BFbjc2012406_CR37","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/MAJ.0b013e31812dfe1e","volume":"334","author":"X Yao","year":"2007","unstructured":"Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334: 115\u2013124","journal-title":"Am J Med Sci"},{"key":"BFbjc2012406_CR38","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","volume":"49","author":"X Zhu","year":"2007","unstructured":"Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49: 186\u2013193","journal-title":"Am J Kidney Dis"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2012406.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2012406","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2012406.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:10:32Z","timestamp":1684415432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2012406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,18]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["BFbjc2012406"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2012.406","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,18]]}}}